Site-specific glycan analysis of the SARS-CoV-2 spike
暂无分享,去创建一个
Daniel Wrapp | Jason S. McLellan | J. McLellan | D. Wrapp | M. Crispin | Yasunori Watanabe | Max Crispin | Joel D. Allen | Yasunori Watanabe | J. Allen
[1] F. Krammer,et al. SARS-CoV-2 Vaccines: Status Report , 2020, Immunity.
[2] John R Yates,et al. Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer , 2018, Nature Communications.
[3] N. Packer,et al. Emerging roles of protein mannosylation in inflammation and infection. , 2016, Molecular aspects of medicine.
[4] Alexis Rohou,et al. cisTEM: User-friendly software for single-particle image processing , 2017, bioRxiv.
[5] John R Yates,et al. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein , 2017, Nature Communications.
[6] R. Dwek,et al. Exploiting the defensive sugars of HIV-1 for drug and vaccine design , 2007, Nature.
[7] Bette Korber,et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. , 2004, Glycobiology.
[8] A. Walls,et al. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.
[9] B. Hogue,et al. Coronavirus envelope (E) protein remains at the site of assembly , 2015, Virology.
[10] Darrell J Irvine,et al. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers , 2019, Science.
[11] D. Roote,et al. Status Report , 2006, Journal of periodontology.
[12] M. Renfrow,et al. Glycosylation of viral surface proteins probed by mass spectrometry , 2019, Current Opinion in Virology.
[13] John P. Moore,et al. Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer , 2016, Journal of Virology.
[14] M. Crispin,et al. Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope , 2015, Journal of Virology.
[15] William R. Schief,et al. Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV , 2014, Science Translational Medicine.
[16] Silke Stertz,et al. The intracellular sites of early replication and budding of SARS-coronavirus , 2007, Virology.
[17] R. Desrosiers,et al. Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding , 2016, Scientific Reports.
[18] Alexis Rohou,et al. cisTEM: User-friendly software for single-particle image processing , 2018 .
[19] Pauline M Rudd,et al. Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein , 2010, Virology.
[20] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[21] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[22] Young Do Kwon,et al. Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G , 2016, Cell.
[23] K. Khoo,et al. Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans , 2020, Proceedings of the National Academy of Sciences.
[24] Andrea Marzi,et al. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.
[25] Zachary T. Berndsen,et al. Vulnerabilities in coronavirus glycan shields despite extensive glycosylation , 2020, Nature Communications.
[26] D. Burton,et al. Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization , 2018, Immunity.
[27] James E. Crowe,et al. Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus , 2010, Science.
[28] I. Wilson,et al. Exploitation of glycosylation in enveloped virus pathobiology , 2019, Biochimica et Biophysica Acta (BBA) - General Subjects.
[29] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[30] Paul Emsley,et al. Structural analysis of glycoproteins: building N-linked glycans with Coot , 2018, Acta crystallographica. Section D, Structural biology.
[31] David J. Harvey,et al. Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen , 2018, Cell reports.
[32] Barney S. Graham,et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.
[33] David Nemazee,et al. Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.
[34] Raymond A. Dwek,et al. Emerging Principles for the Therapeutic Exploitation of Glycosylation , 2014, Science.
[35] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[36] D. Veesler,et al. Structural and functional analysis of a potent sarbecovirus neutralizing antibody , 2020 .
[37] Amalio Telenti,et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.
[38] Thomas Strecker,et al. Structure of the Lassa virus glycan shield provides a model for immunological resistance , 2018, Proceedings of the National Academy of Sciences.
[39] Weston B Struwe,et al. Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein , 2016, Cell reports.
[40] Chih-Jen Wei,et al. Cross-Neutralization of 1918 and 2009 Influenza Viruses: Role of Glycans in Viral Evolution and Vaccine Design , 2010, Science Translational Medicine.
[41] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.